Search - tctmd.com

Displaying 101 - 120 of 206

Sort: Relevancy | Date

News Daily News

New Advanced Training Outlined for Future Vascular Medicine Specialists

Michael O'Riordan

January 21, 2021

News Daily News

Plaque Burden, Not Coronary Stenosis, Linked to Future Events in Stable CAD

Michael O'Riordan

December 07, 2020

News Daily News

Coronary Calcium Scans May ID Patients Who Benefit From Aspirin

Michael O'Riordan

October 30, 2020

News Conference News TCT 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

Todd Neale

October 21, 2020

News Conference News EAS 2020

Just One-Third of European Patients Get to LDL Cholesterol Goals

Michael O'Riordan

October 13, 2020

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Conference News EAS 2020

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Michael O'Riordan

October 07, 2020

News Daily News

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

Michael O'Riordan

September 22, 2020

News Daily News

Free CAC Scans for ASCVD Risk Capture More Women, Minorities, and Low-Income Adults

Michael O'Riordan

September 02, 2020

News Conference News ESC 2020

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

Yael L. Maxwell

September 02, 2020

News Daily News

Young Patients With Premature ASCVD Less Likely to Receive Statins, Aspirin

Michael O'Riordan

August 25, 2020

News Daily News

PAD Patients Undertreated With Statins Despite Elevated CV Risk

L.A. McKeown

July 13, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Todd Neale

March 28, 2020

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Daily News

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Shelley Wood

March 10, 2020

News Daily News

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

Shelley Wood

March 04, 2020

News Daily News

Trials of New Cancer Drugs Failing to Address Potential CV Risks

Todd Neale

February 10, 2020

News Daily News

Hypertension Starts Years Earlier in Women Than Men, Serial BP Shows

L.A. McKeown

January 17, 2020

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

Advertisement

New Advanced Training Outlined for Future Vascular Medicine Specialists

Plaque Burden, Not Coronary Stenosis, Linked to Future Events in Stable CAD

Coronary Calcium Scans May ID Patients Who Benefit From Aspirin

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

Just One-Third of European Patients Get to LDL Cholesterol Goals

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

Free CAC Scans for ASCVD Risk Capture More Women, Minorities, and Low-Income Adults

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

Young Patients With Premature ASCVD Less Likely to Receive Statins, Aspirin

PAD Patients Undertreated With Statins Despite Elevated CV Risk

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

Trials of New Cancer Drugs Failing to Address Potential CV Risks

Hypertension Starts Years Earlier in Women Than Men, Serial BP Shows

FDA Approves Icosapent Ethyl for Reducing CVD Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content